Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
This grant funds multidisciplinary teams to develop and validate biomarkers and imaging tools for early detection of pancreatic cancer and its precursors, focusing on high-risk individuals and collaborative research.
Funder: National Institutes of Health
Due Dates (Anticipated): July 2026 (Full application deadline, projected)
Funding Amounts: Expected 10 awards; typical NIH U01 cooperative agreement—award size and duration vary, see program for details.
Summary: Supports multidisciplinary research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of precursor lesions through biomarker and imaging development, validation, and collaborative consortium activities.
Key Information: This is a forecasted opportunity; all deadlines are projected and subject to change.
Description
This opportunity, issued by the National Cancer Institute (NCI) at NIH, solicits applications for Research Units (RUs) as part of the Pancreatic Cancer Detection Consortium (PCDC). The PCDC aims to advance early detection of pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions, focusing on identifying high-risk patients and candidates for early intervention. Supported projects may involve:
- Development and validation of molecular and imaging biomarkers for early detection of PDAC and precursor lesions
- Identification of markers in bodily fluids and pancreatic cysts to predict cancer progression
- Screening approaches for high-risk populations (due to genetics, family history, or precursor lesions)
- Use of machine learning and computational methods for biomarker discovery/validation
- Collection of longitudinal biospecimens to build a biorepository
Consortium members are expected to participate in collaborative activities, sharing data, biospecimens, and ideas. A separate Management and Data Coordination Unit will support study design, data harmonization, and stewardship.
